Sirona Biochem Corp.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology

Other Names/Subsidiaries

  • TFChem
  • Sirona Laboratories
See more in Biomedtracker

Latest on Sirona Biochem Corp.

Scrip

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

 
• By Anju Ghangurde, Joseph Haas, Ian Haydock, Jung Won Shin, Lisa Takagi, Dexter Jie Yan, and Brian Yang

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Biocytogen Licenses Antibodies For

Scrip

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

 
• By Dexter Jie Yan

On 29 November, Shanghai-based Full-Life Technologies Limited announced it would acquire Focus-X Therapeutics, a two-year-old US biotech focusing on the development of peptide receptor radionuclide

In Vivo

Deals Shaping The Medical Industry, February 2014

IN VITRO DIAGNOSTICS Alliances NovaMedica LLC Venter Pharma SL Russian specialty pharmaco NovaMedica LLC received exclusive rights to commercialize Spanish firm Venter Pharma SL ’s lactose into

Scrip

Fosun subsidiary Wanbang licenses Sirona's SGLT2 inhibitor

 
• By Gemma Collier

Canadian biotech Sirona Biochem and Wanbang Pharma, a subsidiary of Chinese pharma company Fosun, have struck a licensing deal for Sirona's preclinical SGLT2 inhibitor in China. Wanbang will pay Siron